Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma
Journal of Clinical Oncology (JCO) Podcast · Journals Online Team
December 19, 20127m 27s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.